Research press release




MRSAはヒトを死に至らしめる恐れがある細菌で、MRSA感染症は治療が難しい。その理由は、多くの菌株が従来の抗菌剤に対する抵抗性を獲得していることだけでなく、代謝的に不活性で抗菌剤耐性を持つ持続生残細胞(persister)の一群も生成されることにある。今回、Eleftherios Mylonakisたちの研究グループは、実験室での分析で、MRSAの増殖中の細胞と持続生残細胞の両方を死滅させる2種類の合成レチノイド化合物を同定した。そのうち1つは、慢性MRSA感染症のマウスモデルの治療にも有効だった。


A new class of antibiotics can kill methicillin-resistant Staphylococcus aureus (MRSA) bacteria in a preclinical mouse model, a Nature paper reports. With antimicrobial resistance an increasingly serious threat to global public health, it is hoped that the study will aid the development of new, effective, clinically useful antibiotic drugs.

MRSA is a potentially lethal bacterium that is difficult to treat, not only because many strains are now resistant to conventional antibiotics, but also because it forms subpopulations of metabolically inactive, antibiotic-tolerant ‘persister’ cells. Eleftherios Mylonakis and colleagues identified two synthetic retinoid compounds that kill both growing and persister MRSA cells in a lab-based assay. One of these compounds was also effective in treating a mouse model of chronic MRSA infection.

The compounds, which are analogues of vitamin A, have low levels of toxicity and work by disrupting bacterial membranes. Both work synergistically with the common antibiotic gentamicin, and the authors think it is unlikely that bacteria will develop resistance to them. Currently, over 4,000 natural and synthetic retinoids have been described, so it is possible that more antimicrobial candidates will be found amongst them. In the meantime, further development of these two compounds is needed in order to improve their safety profile, and move them closer to clinical trials.

doi: 10.1038/nature26157

「Nature 関連誌注目のハイライト」は、ネイチャー広報部門が報道関係者向けに作成したリリースを翻訳したものです。より正確かつ詳細な情報が必要な場合には、必ず原著論文をご覧ください。

メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週最新のNature 関連誌のハイライトを皆様にお届けいたします。